Peptide therapy claims on TikTok: what the evidence actually shows

What's this video probably claiming?

Michael Ward, NP, is a nurse practitioner who regularly posts about peptide therapy to a growing audience. Given the category context, this video is likely a response to a follower question about one or more peptides, possibly BPC-157, TB-500, CJC-1295/ipamorelin, or GHK-Cu. The format is probably a reassuring explainer, walking through what a peptide does, why someone might use it, and what results to expect. These reply-style videos tend to frame peptides as accessible, low-risk tools for healing, performance, or anti-aging. The tone is usually clinical enough to sound credible but optimistic enough to drive interest. That combination is exactly what regulators and skeptical readers should scrutinize. We do not have the transcript yet, so this is a topical analysis of the claims most commonly made in this content category by practitioners with this profile.

What does the science actually show?

The honest answer is: it depends enormously on which peptide you are talking about, and the human evidence is thin across the board. BPC-157 has shown real wound-healing and anti-inflammatory effects in rodent models, but as of 2024 there are zero completed randomized controlled trials in humans. Sikiric et al. have published extensively in journals like Current Pharmaceutical Design, but their work is almost entirely preclinical. TB-500 (thymosin beta-4) similarly has promising animal data on tissue repair, with one phase II trial in cardiac patients (Goldstein et al., 2012, Annals of the New York Academy of Sciences) showing modest signal but no approved indication. CJC-1295 combined with ipamorelin does produce measurable increases in growth hormone and IGF-1, with Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) documenting sustained GH elevation at doses around 30 mcg/kg, but whether that translates to meaningful clinical outcomes in healthy adults is not established. GHK-Cu has real collagen-stimulating data in vitro. MK-677 is an oral ghrelin mimetic, not technically a peptide, and its long-term safety data in healthy populations is essentially absent.

Where does the social media noise diverge from clinical reality?

The gap is significant. On TikTok, peptides are framed as the thing your doctor does not know about yet, implying that lack of mainstream adoption reflects ignorance rather than a legitimate absence of evidence. That framing is misleading. The FDA placed BPC-157 and TB-500 on its list of bulk drug substances that may not be used in compounding in 2023, citing inadequate safety data, not bureaucratic caution. Practitioners posting enthusiastic explainers rarely mention that most peptide products used in the US come from compounding pharmacies operating under 503A or 503B frameworks, with no requirement to demonstrate bioequivalence to anything. Semax and selank, nootropic peptides developed in Russia, have some published clinical data in Eastern European journals, but those studies are small, not independently replicated, and conducted in patient populations, not healthy biohackers. The jump from patient to performance use is an assumption, not a finding.

What should you actually know?

If you are watching a healthcare provider discuss peptides on TikTok, apply the same skepticism you would to any health claim made in a 60-second video. Ask whether the evidence being cited is in humans or animals, whether it is replicated, and whether the population studied matches you. Peptide therapy is not uniformly dangerous, but it is also not uniformly safe or proven. The risk profile varies by compound, source, dose, and individual health status. Compounded peptides are not FDA-approved drugs. Their purity, sterility, and concentration depend entirely on the compounding pharmacy's quality controls. A legitimate telehealth provider will acknowledge those limitations directly rather than glossing over them with enthusiasm about results. If a provider is not mentioning FDA regulatory status, compounding source, or the limits of existing human data, that is a gap worth pressing on before you start injecting anything.